Pediatrix Q1 GAAP EPS $0.36, Adj. EPS $0.44; revenue $476M, beat expectations

Pediatrix Medical Group, Inc.

2026-Q1 EPS reported $0.36 revenue$476,196,000

Net revenue $476.2M, up 4% YoY from $458.4M; same-unit revenue grew 2.8%.
Adjusted EBITDA $58.2M vs $49.2M YoY; net income $29.6M ($0.36 diluted) vs $20.7M ($0.24).
Same-unit volume down 1.6% (hospital services -1.5%, office -3.3%) but reimbursement up 4.4%.
Reaffirmed FY2026 Adjusted EBITDA guidance range of $280M-$300M.
Used $21.5M for share repurchases and $7.0M for acquisitions in Q1.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Pediatrix Medical Group, Inc. reported three months ended March 31, 2026 results: revenue $476 million, net income $30 million, EPS $0.36 per share. Guidance reaffirmed.

Period: three months ended March 31, 2026
Revenue: $476 million
Net income: $30 million
EPS: $0.36 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

ended March 31, 2026. On a non-GAAP basis, Pediatrix reported Adjusted EPS of $0.44. For the 2026 first quarter, Pediatrix reported the following results: • Net revenue of $476 million; • Net income of $30 million; and • Adjusted EBITDA of $58 million. “Our first quarter operating results exceeded our expectations, driven by top-line growth,” said Mark S.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Pediatrix Medical Group, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-204982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.